10x Genomics
104 hedge funds and large institutions have $2.45B invested in 10x Genomics in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 11 closing their positions.
209% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 11
122% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 18
84% more call options, than puts
Call options by funds: $8.79M | Put options by funds: $4.77M
37.33% more ownership
Funds ownership: 147.35% → 184.68% (+37%)
22% more funds holding
Funds holding: 85 → 104 (+19)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
4% more capital invested
Capital invested by funds: $2.35B → $2.45B (+$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$309M |
| 2 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
+$299M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$61.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$46.4M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$113M |
| 2 |
JCM
JS Capital Management
New York
|
-$20.4M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$19.5M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$11.9M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$11.4M |
TXG Hedge Fund Activity: Q1 2020 in Review
104 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2020, worth a combined $2.45B — up 4.3% from $2.35B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TXG positions and 11 closed out — a net gain of 23 holders — while 40 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $309M. The largest seller was Foresite Capital Management I, cutting an estimated $113M.
- 104 institutional investors held 10x Genomics (TXG) as of Q1 2020, up from 85 in Q4 2019.
- Funds reported $2.45B of 10x Genomics stock for Q1 2020, up 4.3% quarter-over-quarter.
- 34 funds opened new 10x Genomics positions in Q1 2020 and 11 closed out, a net change of +23 holders.
- The largest 10x Genomics buyer in Q1 2020 was Morgan Stanley, an estimated $309M added.
- The largest 10x Genomics seller in Q1 2020 was Foresite Capital Management I, an estimated $113M sold.
Based on aggregated 13F filings for Q1 2020.